Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Shares Outstanding (Weighted Average): 2010-2025

Historic Shares Outstanding (Weighted Average) for Ligand Pharmaceuticals (LGND) over the last 16 years, with Sep 2025 value amounting to $19.6 million.

  • Ligand Pharmaceuticals' Shares Outstanding (Weighted Average) rose 7.27% to $19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.6 million, marking a year-over-year increase of 7.27%. This contributed to the annual value of $18.9 million for FY2024, which is 8.37% up from last year.
  • According to the latest figures from Q3 2025, Ligand Pharmaceuticals' Shares Outstanding (Weighted Average) is $19.6 million, which was up 1.57% from $19.3 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Shares Outstanding (Weighted Average) registered a high of $19.6 million during Q3 2025, and its lowest value of $16.6 million during Q1 2021.
  • For the 3-year period, Ligand Pharmaceuticals' Shares Outstanding (Weighted Average) averaged around $18.2 million, with its median value being $18.0 million (2024).
  • Data for Ligand Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY climbed of 8.75% (in 2025) over the last 5 years.
  • Ligand Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarterly) stood at $16.7 million in 2021, then rose by 1.09% to $16.9 million in 2022, then grew by 3.21% to $17.4 million in 2023, then rose by 8.37% to $18.9 million in 2024, then increased by 7.27% to $19.6 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $19.6 million for Q3 2025, versus $19.3 million for Q2 2025 and $19.3 million for Q1 2025.